Illumina (ILMN): A Beat, a Raise, and a Stock That Already Doubled | Q2 2026

Illumina, Inc. (ILMN) Q2 2026 — Revenue $1.159B, +9.5% and ahead of consensus; organic +6.5%, rest-of-world organic (ex-China) +8.1%. Non-GAAP diluted EPS $1.31 vs $1.19 and above the ~$1.25 expected. GAAP diluted EPS FELL to $1.35 from $1.49 on a strategic-investment comp. FY26 guidance RAISED: revenue $4.60-4.64B (from $4.52-4.62B) and non-GAAP EPS $5.30-5.40 (from $5.15-5.30) - but non-GAAP operating margin guidance was left UNCHANGED at 23.4-23.6%. Reported after the close on July 30; the stock had closed that session +5.3% at $205.09, a 52-week high, having already doubled in 12 months. The quarter was good. The price is the problem. Illumina beat and raised, but non-GAAP gross margin fell 120bps to 68.2% (from 69.4%) and non-GAAP operating margin fell 130bps to 22.5% (from 23.8%) - GAAP margins only expanded because the prior-year quarter carried a $23M intangible impairment in cost of revenue. Free cash flow fell 21% to $162M from $204M; year-to-date FCF is $412M, exactly flat. Trailing twelve-month FCF is ~$932M and has stopped growing. Underneath the 5% consumables line is a split: clinical consumables +15% ex-China (>20% in the US and Canada), research and applied consumables -7% with management explicitly assuming NO recovery this year. Greater China is $56M, -19%, still on the unreliable entity list - it cost 1.6pts of growth. And for the first time there is credible competition at the top end: Roche launched Axelios 1 on June 29, 2026 at ~$750,000, roughly half a top-spec NovaSeq X. Run the reverse DCF and the $205 price asks for $1.53B of free cash flow starting today against the ~$950M we model. THE CALL: AVOID (4/5, GREAT FRANCHISE, THE RE-RATING HAS OUTRUN IT) — base-case value ~$135.0 vs ~$205.09 today. KEY METRICS: - Revenue $1,159M +9.5%; organic +6.5%; ROW organic ex-China +8.1%; China drag 1.6pts - Product revenue $982M; service and other $177M - Sequencing consumables $775M +5% (clinical +15% ex-China, research/applied -7%) - Sequencing instruments $125M +31%; service and other $154M; microarrays/other $105M - USCAN $653M +13% organic; EMEALA $368M flat; APAC $82M +9%; Greater China $56M -19% - GAAP gross margin 66.4% (vs 65.6%); non-GAAP 68.2% (vs 69.4%) - DOWN 120bps - GAAP operating margin 21.1% (vs 20.2%); non-GAAP 22.5% (vs 23.8%) - DOWN 130bps - R&D $252M; SG&A $273M (+16.7%); total opex $525M vs $481M - GAAP diluted EPS $1.35 vs $1.49; non-GAAP $1.31 vs $1.19; net income $207M vs $235M - Other income $15M vs $92M - the entire GAAP EPS decline (strategic investment gains) - Operating cash flow $201M, capex $39M, FCF $162M vs $204M (-21%); YTD FCF $412M, flat - TTM free cash flow ~$932M; cash + ST investments $1,168M; term debt $1,991M - Diluted shares 153M vs 157M; ~$1.8B remaining buyback authorisation - NovaSeq X: >95 placements (model 50-60/qtr); ~83% of volume and 92% of high-throughput gigabases on X, but only 59% of high-throughput consumables revenue - Pull-through per instrument NO LONGER DISCLOSED; clinical customers take 6-9 months to normalise, so 2026 placements mostly benefit 2027 - FY26 guide RAISED: revenue $4.60-4.64B, non-GAAP EPS $5.30-5.40, ROW organic >5% - FY26 non-GAAP operating margin guidance UNCHANGED at 23.4-23.6%; YTD is 22.2%, so H2 must run ~24.5% - Competition: Roche Axelios 1 launched Jun 29 2026 at ~$750k (~half a top-spec NovaSeq X); Element Biosciences raised $277M and is winning mid-throughput - Our DCF: bear $88 / base $125 / bull $161 at 9%; base is $150 at 8% and $107 at 10% - Reverse DCF: at $205.09 (EV ~$32B) the price requires ~$1.53B of FCF today vs ~$950M, or 16% FCF growth for 5 years from a company guiding 6-7% What to watch: Bull trigger: Illumina reinstating annualised pull-through per instrument - a metric it disclosed for a decade and has now retired - plus research and applied consumables returning to growth. Add a China de-listing and fair value moves toward $170. Bear confirmation: instrument revenue growth fading back to single digits after this quarter's +31% (which would mean the NovaSeq X placement surge was a pull-forward); any cut to the unchanged 23.4-23.6% non-GAAP operating margin guide, since H2 has to run at ~24.5% to hit it; or the first quarter where management is asked about Roche's Axelios and cannot answer with a share number. Any two of those and fair value is nearer $100. We would be a real buyer around $120 (~22x forward). Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.